This is the first study that reports CD133+CD44+CD54+ subpopulation of CTCs has a prognostic value in CRC patients with liver metastases, especially those who did not receive surgical treatment for metastases (P < 0.001). This evidence concerns the gene PROM1 and colorectal carcinoma.